Neumora Therapeutics Net Income

The latest net income for NMRA is $-220M as of March 2026. That compares with $-260M in the prior-year period — up 13.8% year over year. That is below the sector sector average of $97M. Investors often review this figure alongside Neumora Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NMRA's net income moved from $-260M to $-220M — a 13.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neumora Therapeutics's operating scale or balance-sheet position.

Against its sector companies, NMRA currently prints $-220M for net income, while the sector average sits near $97M. That is roughly 329.2% below the sector mean. Large gaps often invite a closer look at Neumora Therapeutics's growth, margins, and balance sheet.

A net income figure of $-220M for NMRA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $97M. Explore the charts below for those layers of context.

After noting NMRA's net income ($-220M), review year-over-year change from $-260M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.